Prognosis is much poorer in patients with decompensated cirrhosis due to nonalcoholic steatohepatitis (NASH) than in those with hepatitis B virus (HBV), with the former experiencing more complications and utilizing more healthcare resources, reveals a study.
Patients with chronic hepatitis B virus (HBV) infection who were treated with tenofovir had a lower risk of developing severe COVID-19 illness than those treated with entecavir, according to a study presented at the EASL International Liver Congress (ILC) 2021.
The Fibroscan with XL probe can be used to assess nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery, a recent study has found. The device can be used safely for pre- and postoperative assessments.
In individuals with biopsy-confirmed nonalcoholic steatohepatitis (NASH) with fibrosis, the reductions in liver fat content (LFC) with efruxifermin correlated with improvements in markers of liver injury, fibrosis, metabolic parameters, and histologic features, according to updates from the phase IIa BALANCED study presented at ILC 2021.
In individuals with nonalcoholic fatty liver disease (NAFLD) or presumed nonalcoholic steatohepatitis (NASH), resmetirom, an investigational, once-daily, oral selective thyroid hormone receptor beta agonist, significantly improved several hepatic and cardiovascular (CV) parameters, according to the findings of the phase III MAESTRO-NAFLD1 trial presented at ILC 2021.
Use of rifaximin is well tolerated and lowers the risk of overt hepatic encephalopathy in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunt (TIPS), a recent study has shown.